share_log

Medtronic | 10-Q: Q1 2025 Earnings Report

Medtronic | 10-Q: Q1 2025 Earnings Report

美敦力 | 10-Q：2025财年一季报
美股SEC公告 ·  2024/08/28 04:21

Moomoo AI 已提取核心信息

Medtronic reported Q1 fiscal 2025 revenue of $7.9 billion, up 3% year-over-year, with GAAP diluted EPS of $0.80 compared to $0.59 in the prior year. The growth was driven by strong performance across most businesses, particularly Diabetes (+12%), Neuromodulation (+9%), and Cardiac Rhythm & Heart Failure (+6%). Operating profit increased to $1.28 billion from $1.27 billion last year.The company saw broad-based growth across geographies, with U.S. revenue up 4% to $4.1 billion and international revenue up 1% to $3.8 billion. Performance was particularly strong in the Cardiovascular segment which grew 6% to $3.0 billion, while Neuroscience increased 4% to $2.3 billion. However, results were partially offset by a $90 million charge related to Italian payback accruals.Looking ahead, Medtronic remains focused on innovation and market expansion while managing various macro-economic challenges. The company maintained strong liquidity with $1.3 billion in cash and $6.5 billion in investments at quarter-end. During the quarter, Medtronic issued €3.0 billion in Senior Notes and repurchased 30 million shares at an average price of $82.28 per share.
Medtronic reported Q1 fiscal 2025 revenue of $7.9 billion, up 3% year-over-year, with GAAP diluted EPS of $0.80 compared to $0.59 in the prior year. The growth was driven by strong performance across most businesses, particularly Diabetes (+12%), Neuromodulation (+9%), and Cardiac Rhythm & Heart Failure (+6%). Operating profit increased to $1.28 billion from $1.27 billion last year.The company saw broad-based growth across geographies, with U.S. revenue up 4% to $4.1 billion and international revenue up 1% to $3.8 billion. Performance was particularly strong in the Cardiovascular segment which grew 6% to $3.0 billion, while Neuroscience increased 4% to $2.3 billion. However, results were partially offset by a $90 million charge related to Italian payback accruals.Looking ahead, Medtronic remains focused on innovation and market expansion while managing various macro-economic challenges. The company maintained strong liquidity with $1.3 billion in cash and $6.5 billion in investments at quarter-end. During the quarter, Medtronic issued €3.0 billion in Senior Notes and repurchased 30 million shares at an average price of $82.28 per share.
美敦力报告了2025财年第一季度营业收入为79亿，同比增加3%，GAAP摊薄后每股收益为0.80美元，而上一年为0.59美元。增长主要得益于大多数业务的强劲表现，特别是糖尿病（+12%）、神经调节（+9%）和心脏节律与心力衰竭（+6%）。营业利润从去年的12.7亿增加到12.8亿。该公司在各个地区实现了广泛的增长，美国营业收入增长4%至41亿，国际营业收入增长1%至38亿。心血管领域的表现尤为强劲，增长6%至30亿，而神经科学领域增长4%至23亿。然而，结果部分被与意大利偿还预提相关的9000万费用所抵消。展望未来，美敦力专注于创新和市场扩张，同时应对各种宏观经济挑战。公司维持了强劲的流动性，季度末现金为13亿，投资为65亿。在季度内，美敦力发行了30亿欧元的高级债券，并以每股平均价格82.28美元回购了3000万股股份。
美敦力报告了2025财年第一季度营业收入为79亿，同比增加3%，GAAP摊薄后每股收益为0.80美元，而上一年为0.59美元。增长主要得益于大多数业务的强劲表现，特别是糖尿病（+12%）、神经调节（+9%）和心脏节律与心力衰竭（+6%）。营业利润从去年的12.7亿增加到12.8亿。该公司在各个地区实现了广泛的增长，美国营业收入增长4%至41亿，国际营业收入增长1%至38亿。心血管领域的表现尤为强劲，增长6%至30亿，而神经科学领域增长4%至23亿。然而，结果部分被与意大利偿还预提相关的9000万费用所抵消。展望未来，美敦力专注于创新和市场扩张，同时应对各种宏观经济挑战。公司维持了强劲的流动性，季度末现金为13亿，投资为65亿。在季度内，美敦力发行了30亿欧元的高级债券，并以每股平均价格82.28美元回购了3000万股股份。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    艾里德克斯
    IRIX
    -- 0.999
    Helius Medical Technologies
    HSDT
    -- 0.4200
    VolitionRX
    VNRX
    -- 0.550
    HeartSciences
    HSCS
    -- 2.9600
    Outset Medical
    OM
    -- 12.580
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点